Ovarian transitional cell carcinoma Trials in St. Louis, United States
Conditions / Ovarian transitional cell carcinoma / St. Louis, United States
Research into Ovarian transitional cell carcinoma spans multiple therapeutic approaches and trial phases.
11 total trials for this combination
Showing top 10 of 11 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | ACTIVE_NOT_RECRUITING | — |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | ACTIVE_NOT_RECRUITING | — |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | ACTIVE_NOT_RECRUITING | — |
| NCT02446600 | Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT02446600 | Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | ACTIVE_NOT_RECRUITING | — |
| NCT02502266 | Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | ACTIVE_NOT_RECRUITING | — |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | ACTIVE_NOT_RECRUITING | — |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | ACTIVE_NOT_RECRUITING | — |